Pfizer PFE

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Pfizer to pay $400 million to avert investor class action trial

      Headlines

      Tue, 27 Jan 2015

      NEW YORK, Jan 27 (Reuters) - Pfizer Inc said on Tuesday it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing.

    2. BRIEF- Pfizer CEO says company doesn't need to do a big deal

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Pfizer Inc : * CEO says company doesn't need to do a big deal, would consider worthwhile

    3. Five Consensus Views that Could Prove Wrong in 2015

      Headlines

      Tue, 27 Jan 2015

      We think Technosphere insulin has consistently shown signs that it not only improves upon its struggling predecessor ( Pfizer PFE and Nektar's NKTR Exubera), but also that it has the potential to provide better control of glucose levels than the

    4. UPDATE 1- Pfizer's 2015 forecast disappoints, crimped by generics, dollar

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Pfizer Inc reported stronger-than-expected quarterly sales due to cost cuts and demand for its vaccines and cancer drugs, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar.

    5. Pfizer's 2015 forecast disappoints, crimped by generics, dollar

      Headlines

      Tue, 27 Jan 2015

      (Reuters) - Pfizer Inc reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar.

    6. Pfizer's 2015 forecast disappoints, crimped by generics, dollar

      Headlines

      Tue, 27 Jan 2015

      Jan 27 (Reuters) - Pfizer Inc reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased, but the company forecast 2015 earnings below Wall Street expectations, citing patent expirations and the stronger dollar.

    7. Pfizer Posts Strong 4Q, but Lack of Strong Growth Outlook Is Likely to Drive Acquisitions

      Commentary

      Tue, 27 Jan 2015

      Pfizer reported strong fourth-quarter results ..... estimate for the company. Further, while Pfizer 's research and development haven't been ..... term growth. Turning to the pipeline, Pfizer is playing catch-up with several of its

    8. Pfizer May Go Shopping for Growth

      Headlines

      Tue, 27 Jan 2015

      Pfizer PFE reported strong fourth-quarter results ..... estimate for the company. Further, while Pfizer 's research and development haven't been ..... term growth. Turning to the pipeline, Pfizer is playing catch-up with several of its

    9. Pfizer cuts vaccine price for poor as GAVI group seeks $7.5 bln

      Headlines

      Mon, 26 Jan 2015

      LONDON, Jan 26 (Reuters) - Pfizer is to cut the price of its pneumococcal vaccine Prevenar 13 by 6 percent to $3.10 per dose in poor countries as part of a commitment to the GAVI global vaccines alliance, the U.S. drugmaker said on Monday.

    10. MSF slams expensive vaccines, urges GSK and Pfizer to cut prices

      Headlines

      Tue, 20 Jan 2015

      LONDON, Jan 20 (Reuters) - the international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries.

    « Prev12345Next »
    Content Partners